Literature DB >> 12006367

Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.

Thongchai Pratipanawatr1, Wilailak Pratipanawatr, Clifford Rosen, Rachele Berria, Mandeep Bajaj, Kenneth Cusi, Lawrence Mandarino, Sangeta Kashyap, Renata Belfort, Ralph A DeFronzo.   

Abstract

UNLABELLED: The effects of insulin-like growth factor I (IGF-I) and insulin on free fatty acid (FFA) and glucose metabolism were compared in eight control and eight type 2 diabetic subjects, who received a two-step euglycemic hyperinsulinemic (0.25 and 0.5 mU x kg(-1) x min(-1)) clamp and a two-step euglycemic IGF-I (26 and 52 pmol x kg(-1) x min(-1)) clamp with [3-(3)H]glucose, [1-(14)C]palmitate, and indirect calorimetry. The insulin and IGF-I infusion rates were chosen to augment glucose disposal (R(d)) to a similar extent in control subjects. In type 2 diabetic subjects, stimulation of R(d) (second clamp step) in response to both insulin and IGF-I was reduced by approximately 40-50% compared with control subjects. In control subjects, insulin was more effective than IGF-I in suppressing endogenous glucose production (EGP) during both clamp steps. In type 2 diabetic subjects, insulin-mediated suppression of EGP was impaired, whereas EGP suppression by IGF-I was similar to that of controls. In both control and diabetic subjects, IGF-I-mediated suppression of plasma FFA concentration and inhibition of FFA turnover were markedly impaired compared with insulin (P < 0.01-0.001). During the second IGF-I clamp step, suppression of plasma FFA concentration and FFA turnover was impaired in diabetic vs. control subjects (P < 0.05-0.01).
CONCLUSIONS: 1) IGF-I is less effective than insulin in suppressing EGP and FFA turnover; 2) insulin-resistant type 2 diabetic subjects also exhibit IGF-I resistance in skeletal muscle. However, suppression of EGP by IGF-I is not impaired in diabetic individuals, indicating normal hepatic sensitivity to IGF-I.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006367     DOI: 10.1152/ajpendo.00335.2001

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  18 in total

1.  Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation.

Authors:  P M Yamada; H H Mehta; D Hwang; K P Roos; A L Hevener; K W Lee
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

Review 2.  Diabetes in Patients With Acromegaly.

Authors:  A M Hannon; C J Thompson; M Sherlock
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

3.  Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community.

Authors:  Carolyn S P Lam; Ming-Huei Chen; Sean M Lacey; Qiong Yang; Lisa M Sullivan; Vanessa Xanthakis; Radwan Safa; Holly M Smith; Xuyang Peng; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

4.  Effects of growth hormone on hepatic insulin sensitivity and glucose effectiveness in healthy older adults.

Authors:  Lala Forrest; Caroline Sedmak; Shanaz Sikder; Shivraj Grewal; S Mitchell Harman; Marc R Blackman; Ranganath Muniyappa
Journal:  Endocrine       Date:  2019-01-07       Impact factor: 3.633

Review 5.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

6.  Effects of exercise training and diet on lipid kinetics during free fatty acid-induced insulin resistance in older obese humans with impaired glucose tolerance.

Authors:  Thomas P J Solomon; Jacob M Haus; Christine M Marchetti; William C Stanley; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

7.  A Novel Mutation in Insulin-Like Growth Factor 1 Receptor (c.641-2A>G) Is Associated with Impaired Growth, Hypoglycemia, and Modified Immune Phenotypes.

Authors:  Melanie R Shapiro; Timothy P Foster; Daniel J Perry; Ron G Rosenfeld; Andrew Dauber; James A McNichols; Andrew Muir; Vivian Hwa; Todd M Brusko; Laura M Jacobsen
Journal:  Horm Res Paediatr       Date:  2020-10-28       Impact factor: 2.852

8.  Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.

Authors:  Dan Niculescu; Mariana Purice; Mihail Coculescu
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

Review 9.  Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology.

Authors:  Jason C O'Connor; Robert H McCusker; Klemen Strle; Rodney W Johnson; Robert Dantzer; Keith W Kelley
Journal:  Cell Immunol       Date:  2008-03-05       Impact factor: 4.868

Review 10.  Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus.

Authors:  Min Sun Kim; Dae-Yeol Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.